Drugs · acquisition-cost intelligence
Qsymia
phentermine and topiramate· ingredient topiramateCentrally acting antiobesity products· PHENTERMINE HYDROCHLORIDE 11.25 mg/1; TOPIRAMATE 69 mg/1; PHENTERMINE HYDROCHLORIDE 15 mg/1; TOPIRAMATE 92 mg/1; PHENTERMINE HYDROCHLORIDE 3.75 mg/1; TOPIRAMATE 23 mg/1; PHENTERMINE HYDROCHLORIDE 7.5 mg/1; TOPIRAMATE 46 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$3.21
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other topiramate products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| topiramate | $0.04260 | −$3.17 |
| Topamax | $0.05949 | −$3.15 |
| TOPIRAMATE | $0.30433 | −$2.90 |
| Eprontia | $1.61 | −$1.60 |
| topiramate | $5.66 | +$2.46 |
| Trokendi XR | $9.01 | +$5.80 |
| Topiramate | $22.71 | +$19.50 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.